Clinical features of irreversible rejection after allogeneic uterus transplantation in cynomolgus macaques

Iori Kisu1, Katsura Emoto2, Yohei Masugi2, Yohei Yamada3, Kentaro Matsubara4, Hideaki Obara4, Yusuke Matoba1, Kouji Banno1, Yojiro Kato5, Yoko Saiki6, Iori Itagaki7,8, Ikuo Kawamoto7, Chizuru Iwatani7, Mitsuru Murase7, Takahiro Nakagawa7, Hideaki Tsuchiya7, Hirohito Ishigaki9, Hiroyuki Urano10, Masatsugu Ema9, Kazumasa Ogasawara7,9, Daisuke Aoki1, Kenshi Nakagawa10 & Takashi Shiina11

Uterus transplantation (UTx) is a potential option for women with uterine factor infertility to have a child. The clinical features indicating irreversible rejection of the uterus are unknown. In our experimental series of allogeneic UTx in cynomolgus macaques, six female macaques were retrospectively examined, which were unresponsive to treatment with immunosuppressants (i.e. irreversible rejection). Clinical features including general condition, hematology, uterine size, indocyanine green (ICG) fluorescence imaging by laparotomy, and histopathological findings of the removed uterus were evaluated. In all cases, general condition was good at the time of diagnosis of irreversible rejection and thereafter. Laboratory evaluation showed temporary increases in white blood cells, lactate dehydrogenase and C-reactive protein, then these levels tended to decrease gradually. In transabdominal ultrasonography, the uterus showed time-dependent shrinkage after transient swelling at the time of diagnosis of irreversible rejection. In laparotomy, a whitish transplanted uterus was observed and enhancement of the transplanted uterus was absent in ICG fluorescence imaging. Histopathological findings in each removed uterus showed hyalinized fibrosis, endometrial deficit, lymphocytic infiltration and vasculitis. These findings suggest that uterine transplantation rejection is not fatal, in contrast to rejection of life-supporting organs. Since the transplanted uterus with irreversible rejection atrophies naturally, hysterectomy may be unnecessary.

Uterus transplantation (UTx) has become a potential option for women with uterine factor infertility to have a child, following the first successful delivery by Brännström et al. in Sweden in 2014. This major achievement attracted considerable attention worldwide, and many centers have recently begun clinical application of UTx, leading to more than 60 procedures and 18 live births. Despite this success, UTx is still in an experimental stage and there are many clinical and technical issues to be resolved for its full clinical establishment. In particular, rejection remains as a concern in this procedure. There have been several reported cases of rejection after UTx...
in humans\textsuperscript{4–9} and pathological criteria for uterine rejection have been proposed by the group in Sweden\textsuperscript{10}. All of these cases overcame rejection with subsequent immunosuppressive therapy and some achieved successful live birth after treatment of the rejection\textsuperscript{1,8}.

Organ elimination due to rejection after transplantation of a life-supporting organ generally results in a fatal outcome. However, UTx is not a vital organ transplantation, and organ elimination due to rejection might not lead to life-threatening conditions. However, there are no reports of a uterus that became non-functional or was removed due to irreversible rejection that was resistant to treatment, and the clinical features indicating irreversible rejection of the uterus are unclear.

Our team in Japan launched UTx research in 2009 using approximately 100 cynomolgus macaques, which are anatomically and physiologically similar to humans. Since then, we have accumulated a large archive of results, including examination of uterine blood flow, surgical procedures for autologous and allogeneic UTx, organ perfusion methods in deceased donor models, immunological response and rejection, and ischemia/reperfusion injury\textsuperscript{11}. In this experimental series, we had cases of hysterectomy after allogeneic UTx due to diagnosis of irreversible rejection that was resistant to immunosuppressants.

These cases arose from difficulty and limitations in postoperative managements and monitoring in cynomolgus macaques\textsuperscript{12,13}, which are likely to develop rejection and have high antigenicity, in contrast to humans\textsuperscript{14}. These events may be of value in understanding rejection in UTx because similar events have not been observed in humans. Therefore, in this study, we retrospectively examined the clinical features associated with irreversible rejection after allogeneic UTx in cynomolgus macaques.

Results

Irreversible rejection. In this study, irreversible rejection was defined as progressive rejection in spite of the following treatments. Steroid pulse therapy was administered in all cases and ATG in cases 4 and 5, but the rejections were unresponsive and not overcome by these treatments. Moreover, necrotic change in uterine tissues was often observed histologically. The cases were diagnosed as irreversible rejection on postoperative day (POD) 11, 35, 35, 41, 67 and 206 (Table 1).

Well-being of the animals. In all cases, general condition of the animals (activity, appetite, bowel movement, vomiting, urination) was good at the time of diagnosis of irreversible rejection and thereafter. No animals did not show body weight loss greater than 15%. In cases 2, 5 and 6, continuous vaginal bleeding was observed before and/or after the day of irreversible rejection.

Laboratory evaluation. Hematology and blood chemistry in all animals showed temporary increases in white blood cells (WBC), lactate dehydrogenase (LDH), and C-reactive protein (CRP) before and after rejection was diagnosed (Fig. 1). Thereafter, these levels tended to decrease gradually. There were no marked changes in electrolytes or in liver and renal functions.

Assessment of the transplanted uterus by ultrasonography. In transabdominal ultrasonography, the uterus was swollen at the time of diagnosis of irreversible rejection (Fig. 2). The uterus then showed time-dependent shrinkage (Fig. 3), which made it difficult to identify blood flow in the uterine artery on duplex Doppler ultrasonography. The endometrium of the uterus was not detected in all cases.

Gross findings and ICG fluorescence imaging in laparotomy. Autopsy in cases 1–6 was performed on POD 85, 196, 126, 104, 103 and 265, respectively, because of irreversible rejection that was resistant to additional immunosuppressant therapy. Laparotomy showed a white shrinking uterus that was highly adhesive with surrounding tissues, especially to the bladder, the greater omentum and rectum (Fig. 4A), in cases other than cases 4 and 5. In cases 4 and 5, a whitish swollen transplanted uterus was observed (Fig. 4B). Moreover, the uteri of all cases were hard and sclerotic by gross diagnosis. In ICG fluorescence imaging, enhancement of the transplanted uterus was absent in all cases (Fig. 5).

Pathological findings of the removed uterus. Histologically, compared to the normal uterus (Fig. 6A–C), uteri of the six cases showed no endometrium and myometrium which were replaced by sclerotic fibro-

| Case | POD of irreversible rejection | Treatment for rejection | POD of autopsy |
|------|-------------------------------|-------------------------|----------------|
| 1    | 11                            | Steroid pulse           | 85             |
| 2    | 35                            | Steroid pulse           | 196            |
| 3    | 35                            | Steroid pulse           | 126            |
| 4    | 41                            | Steroid pulse + ATG     | 104            |
| 5    | 67                            | Steroid pulse + ATG     | 103            |
| 6    | 206                           | Steroid pulse           | 265            |

Table 1. Summary of the timing of irreversible rejection in cases 1–6. POD postoperative day, ATG antithymocyte globulin.
sis (Fig. 6D–F) or coagulative necrosis (Fig. 6G–I), which suggested of end stage of the rejection. All cases demonstrated perivascular lymphocytic inflammation, and some cases showed vascular occlusion and/or fibrin thrombi. Inflammation was more severe in perimetrium than in endometrium and myometrium. These histologic findings, loss of endometrial and myometrial structure, indicated that these uteri were no longer functional.

Figure 1. Changes in WBC, LDH and CRP before and after irreversible rejection. WBC, LDH and CRP temporarily increased before and after diagnosis of irreversible rejection, and then tended to decrease gradually (day 0 = day of diagnosis of irreversible rejection).

Figure 2. Transabdominal ultrasonography of the long axis of the uterine body in case 5. (A) The uterine body (28.4 × 17.6 mm: long axis × anteroposterior diameter) after surgery. (B) An enlarged uterine body (60.0 × 28.1 mm: long axis × anteroposterior diameter) without an endometrium was found at the time of diagnosis of irreversible rejection.
**Discussion**

An important goal of UTx is improving quality of life (QOL) for women with uterine factor infertility by allowing these women to have a child, in contrast to transplantation of life-supporting organs. UTx has provided great hope to couples with no children due to uterine factor infertility. However, various risks are involved in organ transplantation, and rejection is a particular concern. The antigenicity of a transplanted organ depends on the organ type and is unclear for the uterus. A pregnant uterus allows a non-self organism to develop within, and thus may be presumed to maintain immune tolerance. On the other hand, organs such as skin, small intestine and lungs that are in contact with the external environment have well-developed immune mechanisms that are likely to cause rejection. The uterus is similarly in contact with the external environment via the vagina, and this may explain the strong potential for rejection of a transplanted uterus.

Some cases of human UTx have resulted in uterine rejection\(^4-9\), but none have required hysterectomy due to refractory rejection. Organ elimination due to rejection after transplantation of a life-supporting organ generally results in a fatal outcome. Since UTx is not life-supporting, but focused on improving QOL, particular attention should be paid to the safety of the healthy recipient. The clinical features of irreversible rejection after UTx are unknown, including the potential mortality that occurs in other organ transplantations, and preparation for unexpected events after UTx is important. Thus, in this study we examined six cynomolgus macaques in which irreversible rejection occurred in our experimental series of allogeneic UTx to clarify the clinical features of irreversible rejection. The main features found were temporary increases in WBC, LDH and CRP before and after irreversible rejection, a swollen uterus at the time of irreversible rejection that then shrinks over time, and a good general condition. In laparotomy, the uterus without uterine blood flow was highly adhesive with surrounding tissues, especially to the omentum and rectum.

**Figure 3.** Changes in the long axis diameter of the uterus before and after irreversible rejection. The uterus was swollen at the time of diagnosis of irreversible rejection, and then showed time-dependent shrinkage (day 0 = day of diagnosis of irreversible rejection).

**Figure 4.** Macroscopic findings in the pelvis at autopsy in case 3 (A) and case 4 (B). (A) A whitish atrophic uterus (yellow triangles) adhered to the omentum and bladder. (B) A swollen uterus that was highly adhesive with surrounding tissues, especially to the omentum and rectum.
surrounding tissues. Pathological findings of the uterus showed hyalinization in the interstitium in all uterine layers, with an endometrial deficit.

The increases in WBC and CRP imply an inflammatory response, and elevated LDH suggests cell breakdown due to rejection. In conventional life-supporting organ transplants, clinical symptoms and biochemical data can be used for monitoring of rejection, instead of biopsy. In contrast, the uterus is not a life-supporting organ and rejection is not immediately life-threatening and is frequently asymptomatic; therefore, no clear findings showing rejection have not been reported in human UTx. The biochemical findings above may be one indicator; however, these findings are often caused by irreversible rejection and it is likely to be difficult to recover uterine function once they occur. Thus, monitoring of rejection by an alternative means to biopsy is more difficult in UTx than in life-supporting organ transplantation.

The swelling of the uterus at the time of rejection shows inflammatory edema due to rejection, and the subsequent shrinkage reflects cell damage, necrotic cell death, and hyalinization and formation of granulation tissues due to ischemia over time, resulting in atrophy. The uteri in cases 4 and 5 were still swollen at autopsy, but it is likely that these uteri will be atrophic thereafter because these cases could not overcome uterine rejection. These processes also occur in life-supporting organs, such as in kidney and liver transplantation.

A major concern in UTx is whether a uterus with irreversible rejection should be removed. Such a uterus is not likely to cause serious problems after rejection and subsequent uterine atrophy and loss of function because the uterus is not a vital organ. This study also showed that general condition remained good in the macaques in which irreversible rejection occurred. Likewise, a good general condition is maintained in macaques with an atrophied uterus after warm ischemia for 8 h, which we used to examine the allowable warm ischemic time and ischemic reperfusion injury of the uterus in cynomolgus macaques. Thus, vital organs result in life-threatening conditions if their function is lost, but the uterus is not critical for survival. This difference from other life-supporting organs is an advantage of non-life-supporting organ transplantation.

In kidney transplantation, chronic allograft dysfunction is a chronic, progressive, and irreversible state of a transplanted kidney and one of the leading causes of allograft loss among kidney transplant recipients. In such a case, hemodialysis is introduced as an alternative life-saving treatment. The graft will gradually be atrophied if it is left in the abdomen, and whether an asymptomatic failed renal allograft should be removed before retransplantation is still controversial. The reported rate of surgical allograft nephrectomy after graft failure varies from 20 to 80%, and mainly depends on the center policy. Some investigators have advocated against removal of an asymptomatic failed allograft due to the morbidity and mortality associated with transplant nephrectomy. In contrast, others have contended that a failed allograft is a source of sepsis or chronic inflammation that may lead to complications, and therefore, should be routinely removed. There is no consensus on the timing and indications for allograft nephrectomy.

Unsurprisingly, continuation of immunosuppression after graft failure results in an increase in infectious complications. Therefore, after early graft failure the graft is often removed to prevent acute rejection and allow rapid reduction or complete withdrawal of immunosuppressive medication. In auxiliary partial orthotopic liver transplantation (APOLT), a partial liver graft is implanted in an orthotopic position after leaving behind part of the native liver, which has a potential advantage of immunosuppression withdrawal in acute liver failure. In this technique, withdrawal of immunosuppressants can be gradual, so that the graft undergoes slow rejection and ultimately becomes atrophic and fibrotic, while the native liver continues to regenerate to compensate for the loss in graft volume. However, the atrophic graft may have to be removed after immunosuppression withdrawal if it becomes infected.

Given this background, it is uncertain if an atrophic uterus after irreversible rejection should be left in the pelvis or removed. Continuous rejection under immunosuppressants leads to promote infection because the...
uterine cavity is in contact with the outside of the body through the vagina, whereas kidney and liver do not contact to the outside directly. In the first Swedish trial of UTx, the patient had repeated intrauterine infection after UTx and the uterus had to be resected. We also experienced this situation in cynomolgus macaques that had abscesses temporarily present in the uterine cavity after allogeneic UTx in which continuous rejection occurred. Since organ transplant recipients receive immunosuppressants, they have higher risks for infection than general patients. Intraabdominal infection is occasionally fatal and hysterectomy should be the best choice to prioritize the safety of the recipient in such a situation.

One concern with hysterectomy is that the rejected uterus is likely to be strongly adhered to the surrounding tissues due to inflammation, which leads to cause more operative complications than in a regular hysterectomy. Furthermore, unless uterine infection occurs, the transplanted graft will atrophy naturally. This natural course supports the opinion that a reoperation for resection of the graft is unnecessary and is likely to lead to risks and burdens for the patient. In reports in humans, post-delivery operations have been routinely performed to allow withdrawal of immunosuppressants to decrease the risk of infection. The question of whether to perform hysterectomy for irreversible uterine rejection, an atrophied uterus, or a transplanted uterus after delivery clearly requires further discussion. Moreover, this study has a limitation that these results in cynomolgus macaques cannot always be extrapolated to humans even if nonhuman primate models have the anatomic and physiologic similarities of their reproductive organs and immune systems to humans.

In conclusion, irreversible rejection after allogeneic UTx in cynomolgus monkeys was associated with increases in WBC, LDH and CRP and uterine shrinkage after transient swelling. General condition was good,
even after the uterus failed due to rejection, which suggests that uterine transplantation rejection is not fatal, in contrast to rejection of life-supporting organs.

Materials and methods

Animals. In our experimental series of allogeneic UTx in cynomolgus macaques, six female recipients of macaques (cases 1–6) (Macaca fascicularis, age 6–13 years; average body weight, 3.85 ± 0.91 kg [mean ± standard deviation]) were retrospectively examined. The six recipients and their donors had compatible ABO blood type and a high degree of polymorphism in the major histocompatibility complex (MHC) gene. All of the recipients were diagnosed with uterine rejection after allogeneic UTx and were unresponsive to treatment with immunosuppressants (i.e. irreversible rejection). The study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council, and was approved by the Animal Care and Use Committee of the Research Center for Animal Life Science, Shiga University of Medical Science, Japan (permit numbers: 2013-4-2, 2016-4-8 and 2019-3-12).

Immunosuppressive treatment. The animals received immunosuppressive treatment as shown in Table 2. Immunosuppressive protocol varied in these animals. As induction treatment, animals received antithymocyte globulin (ATG) (10 mg/kg; Thymoglobulin, Genzyme, Cambridge, MA, USA) intravenously on postoperative day (POD) 0 (the day of surgery) in cases 2 and 3, and 20 mg/kg of ATG on POD 0 and POD 2 in cases 4–6. Rituximab (2 mg/kg; Rituxan; Genentech, San Francisco, CA, USA) before approximately 3 weeks (within 17–23 days before the surgery) and on POD 0 was also given intravenously on POD 0 and POD 2 in case 5 and 6. Maintenance treatment consisted of tacrolimus (TAC) (Prograf; Astellas Pharma) given orally twice a day in case 1, cyclosporine (CyA) (Sandimmune;Novartis, Basel, Switzerland) given subcutaneously in cases 2 and 3, and TAC (Prograf;Astellas Pharma, Tokyo, Japan) given intramuscularly in cases 4–6. The target trough levels for CyA and TAC up to 1 month after surgery were planned to be in the ranges of 300–400 ng/mL and 15–20 ng/mL, respectively, and thereafter were adjusted as required. As another maintenance treatment,mycophenolate mofetil (MMF) (40–100 mg/kg; Cellcept; Chugai Pharmaceutical, Tokyo, Japan) was administered orally from recovery and a high degree of polymorphism in the major histocompatibility complex (MHC) gene. All of the recipients were diagnosed with uterine rejection after allogeneic UTx and were unresponsive to treatment with immunosuppressants (i.e. irreversible rejection). The study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council, and was approved by the Animal Care and Use Committee of the Research Center for Animal Life Science, Shiga University of Medical Science, Japan (permit numbers: 2013-4-2, 2016-4-8 and 2019-3-12).

Immunosuppressive treatment. The animals received immunosuppressive treatment as shown in Table 2. Immunosuppressive protocol varied in these animals. As induction treatment, animals received antithymocyte globulin (ATG) (10 mg/kg; Thymoglobulin, Genzyme, Cambridge, MA, USA) intravenously on postoperative day (POD) 0 (the day of surgery) in cases 2 and 3, and 20 mg/kg of ATG on POD 0 and POD 2 in cases 4–6. Rituximab (2 mg/kg; Rituxan; Genentech, San Francisco, CA, USA) before approximately 3 weeks (within 17–23 days before the surgery) and on POD 0 was also given intravenously on POD 0 and POD 2 in case 5 and 6. Maintenance treatment consisted of tacrolimus (TAC) (Prograf; Astellas Pharma) given orally twice a day in case 1, cyclosporine (CyA) (Sandimmune;Novartis, Basel, Switzerland) given subcutaneously in cases 2 and 3, and TAC (Prograf;Astellas Pharma, Tokyo, Japan) given intramuscularly in cases 4–6. The target trough levels for CyA and TAC up to 1 month after surgery were planned to be in the ranges of 300–400 ng/mL and 15–20 ng/mL, respectively, and thereafter were adjusted as required. As another maintenance treatment,mycophenolate mofetil (MMF) (40–100 mg/kg; Cellcept; Chugai Pharmaceutical, Tokyo, Japan) was administered orally from recovery

| Case | Induction treatment | Maintenance treatment |
|------|---------------------|----------------------|
| 1    | None                | Tac + mPSL           |
| 2    | ATG                 | CyA + MMF + mPSL     |
| 3    | ATG                 | CyA + mPSL           |
| 4    | ATG                 | Tac + MMF + mPSL     |
| 5    | Rxm + ATG           | Tac + MMF + mPSL     |
| 6    | Rxm + ATG           | Tac + MMF + mPSL     |

Table 2. Immunosuppressive treatment in cases 1–6. ATG antithymocyte globulin, CyA cyclosporine, MMF mycophenolate mofetil, mPSL methylprednisolone, Tac tacrolimus, Rxm rituximab.
namic Eye Neo system (Hamamatsu Photonics K.K., Hamamatsu, Japan). Grafted uteri were then removed and evaluated pathologically.

**Endpoints.** Clinical features including general condition, body weight loss, hematology, uterine size by transabdominal ultrasonography, intraabdominal gross findings and ICG fluorescence imaging by laparotomy, and histopathological findings of the removed uterus were evaluated. Day 0 was defined as the day when rejection was diagnosed as irreversible based on the course and pathological findings of biopsy.

Received: 11 April 2020; Accepted: 22 July 2020
Published online: 17 August 2020

**References**

1. Brannstrom, M. et al. Livebirth after uterus transplantation. *Lancet* **385**, 607–616 (2015).
2. Farrell, R. M. et al. Evolving ethical issues with advances in uterus transplantation. *Am. J. Obstet. Gynecol.* https://doi.org/10.1016/j.ajog.2020.01.032 (2020).
3. Kisu, I., Banno, K., Mihara, M., Suganuma, N. & Aoki, D. Current status of uterus transplantation in primates and issues for clinical application. *Fertil. Steril.* **100**, 280–294 (2013).
4. Fageeh, W., Raffa, H., Jabbad, H. & Marzouki, A. Transplantation of the human uterus. *Int. J. Gynecol. Obstet.* **76**, 245–251 (2002).
5. Brannstrom, M. et al. First clinical uterus transplantation trial: a six-month report. *Fertil. Steril.* **101**, 1228–1236 (2014).
6. Johannesson, L. et al. Uterus transplantation trial: 1-year outcome. *Fertil. Steril.* **103**, 199–204 (2015).
7. Chmel, R. et al. Reevaluation and lessons learned from the first 9 cases of a Czech uterus transplantation trial: four deceased donor and 5 living donor uterus transplantations. *Am. J. Transplant.* **19**, 855–864 (2019).
8. Kristek, J. et al. Acute appendicitis in a patient after a uterus transplant: a case report. *World J. Clin. Cases* **7**, 4270–4276 (2019).
9. Pontambekar, S. et al. Laparoscopic-assisted uterus retrieval from live organ donors for uterine transplant: our experience of two patients. *J. Minim. Invasive Gynecol.* **25**, 622–631 (2018).
10. Molle, J. et al. Monitoring of human uterus transplantation with cervical biopsies: a provisional scoring system for rejection. *Am. J. Transplant.* **17**, 1628–1636 (2017).
11. Kisu, I., Banno, K., Matoba, Y., Adachi, M. & Aoki, D. Basic research on uterus transplantation in nonhuman primates in Japan. *J. Obstet. Gynaecol. Res.* **44**, 1871–1881 (2018).
12. Tzakis, A. G. Nonhuman primates as models for transplantation of the uterus. *Fertil. Steril.* **100**(1), 61 (2013).
13. Kisu, I., Banno, K., Mihara, M. & Aoki, D. Uterus transplantation in nonhuman primates. *Fertil. Steril.* **100**, e3 (2013).
14. Kisu, I. et al. Long-term outcome and rejection after allogeneic uterus transplantation in cynomolgus macaques. *J. Clin. Med.* **8**, E1572 (2019).
15. Kisu, I. et al. Allowable warm ischemic time and morphological and biochemical changes in uterine ischemia/reperfusion injury in cynomolgus macaque: a basic study for uterus transplantation. *Hum. Reprod.* **32**, 2581 (2017).
16. Ghyseelen, L. & Naesens, M. Indications, risks and impact of failed allograft nephrectomy. *Transplant. Rev. (Orlando).* **33**, 48–54 (2019).
17. Vavallo, A. et al. Allograft nephrectomy: what is the best surgical technique?. *Transplant. Proc.* **44**, 1922–1925 (2012).
18. Mazuzuchi, E. et al. Surgical complications of graft nephrectomy in the modern transplant era. *J. Urol.* **170**, 734–737 (2003).
19. Rela, M., Kaliamoorthy, I. & Reddy, M. S. Current status of auxiliary partial orthotopic liver transplantation for acute liver failure. *Liver Transpl.* **22**, 1265–1274 (2016).
20. Weiner, J. et al. Long-term outcomes of auxiliary partial orthotopic liver transplantation in preadolescent children with fulminant hepatic failure. *Liver Transpl.* **22**, 485–494 (2016).
21. Kisu, I. et al. Indocyanine green fluorescence imaging for evaluation of uterine blood flow in cynomolgus macaque. *PLoS ONE* **7**, e35124 (2012).

**Acknowledgements**

The authors thank the helpful staff at Research Center for Animal Life Science, Shiga University of Medical Science. This work was supported by the Adaptable and Seamless Technology Transfer Program through Target-Driven Research and Development (A-STEP), AMED (AS2525033N), and the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number 17H05099).

**Author contributions**

I.K. was involved in the design, execution and analysis of the experimental study and drafting of the manuscript. K.E. revised the manuscript. K.E. and Y.M. contributed to the intellectual input in pathology. Y.Y., K.M., H.O., Y.M., Y.K., Y.S., H.I., H.U. and T.S. were involved in the execution of the experimental study. I.I., C.I., M.M., T.N., and H.T. were involved in experimental support in animals. K.B., M.E., K.O., D.A., K.K. and T.S. provided intellectual input and supervision in the overall study design. All authors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to I.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
